Visser-van Balen Hanneke, Geenen Rinie, Kamp Gerdine A, Huisman Jaap, Wit Jan M, Sinnema Gerben
Department of Pediatric Psychology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Acta Paediatr. 2007 May;96(5):715-9. doi: 10.1111/j.1651-2227.2007.00235.x. Epub 2007 Mar 23.
To examine psychosocial functioning of young adults with idiopathic short stature or short stature born small for gestational age after growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment in early adolescence or no intervention.
Thirty young adults (18 treated, 12 untreated; age 17-23 years; on average 5.5 years after the end of treatment) completed questionnaires regarding perceived competence and psychological distress. They and their parents were interviewed on social circumstances, height-related psychosocial stressors and parental worries about prospects in society.
Height gain was on average 2.3 cm more for the treated than for the untreated group. On none of the psychosocial variables differences were found between treated and untreated participants. Compared to Dutch population norms, psychological and social functioning was normal.
GH/GnRHa treatment, with arrest of pubertal development and lower than expected effects on final height, is not observed to lead to long-term negative or positive effects. Both treated and untreated participants go well through the psychosocial transition period of young adulthood. This suggests that, in the long term and independent of hormone treatment, adequate psychosocial adjustment is expected in case of short stature.
研究特发性身材矮小或小于胎龄儿出生的身材矮小的年轻成年人在青春期早期接受生长激素(GH)和促性腺激素释放激素激动剂(GnRHa)治疗或未接受干预后的心理社会功能。
30名年轻成年人(18名接受治疗,12名未接受治疗;年龄17 - 23岁;平均在治疗结束后5.5年)完成了关于自我感知能力和心理困扰的问卷调查。他们及其父母接受了关于社会环境、与身高相关的心理社会压力源以及父母对社会前景担忧的访谈。
治疗组的身高增长平均比未治疗组多2.3厘米。在心理社会变量方面,治疗组和未治疗组参与者之间未发现差异。与荷兰人群规范相比,心理和社会功能正常。
生长激素/促性腺激素释放激素激动剂治疗可使青春期发育停滞,对最终身高的影响低于预期,但未观察到会导致长期的负面或正面影响。接受治疗和未接受治疗的参与者在年轻成年期的心理社会过渡期都进展顺利。这表明,从长期来看,无论是否接受激素治疗,身材矮小的情况下预期都能实现充分的心理社会适应。